The verdict
Our read at a glance.
Whether cosyntropin's established diagnostic role in testing adrenal function is understood as a diagnostic agent rather than a treatment.
- The signal
- Decades of clinical use and study support cosyntropin for the ACTH stimulation test to evaluate adrenal insufficiency. It produces a measurable cortisol rise in people with healthy adrenal function.
- The unknown
- Mostly procedural questions, such as test thresholds and dosing variations, rather than whether the test works.
- Our read
- A standard diagnostic tool, not a treatment. Cosyntropin is well established for testing adrenal function, so the main point is keeping it in its diagnostic lane and distinct from therapeutic ACTH products.
The mechanism
How it works.
Cosyntropin is a synthetic peptide made of the first 24 amino acids of ACTH, the part of the pituitary hormone that carries its full biological activity. Injected as a test dose, it binds melanocortin-2 receptors on the adrenal cortex and signals it to release cortisol, exactly as natural ACTH does. Measuring how much cortisol rises afterward shows whether the adrenal glands can respond normally, which is what the ACTH stimulation test checks.
Safety & regulatory boundary
The consequential part.
Cosyntropin is generally well tolerated as a diagnostic agent, with hypersensitivity reactions the main concern. It is a synthetic ACTH fragment used for diagnosis and is not the same as therapeutic ACTH gel products or compounded or research-labeled cosyntropin, and its diagnostic use does not extend to treatment or wellness claims.
What's next
What we're watching.
Standardization of test protocols and thresholds, and supply or product-identity issues across cosyntropin products.
Context
Why this is discussed.
Cosyntropin is the standard tool for the ACTH stimulation test, a common way to check whether the adrenal glands respond normally.
The evidence base
23 cited references.
Regulatory & labels3
Medical Purchasing Solutions, LLC (FDA label) · 2023
Sandoz Inc (FDA label) · 2024
Medical Purchasing Solutions, LLC (FDA label) · 2024
Registered trials8
ClinicalTrials.gov · COMPLETED · 2004-11-12
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2007-12-17
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2018-09-26
ClinicalTrials.gov · NOT_YET_RECRUITING · 2026-04-01
ClinicalTrials.gov · PHASE3 · COMPLETED · 2021-07-22
ClinicalTrials.gov · NA · RECRUITING · 2022-02-03
ClinicalTrials.gov · RECRUITING · 2025-03-05
ClinicalTrials.gov · PHASE1/PHASE2 · NOT_YET_RECRUITING · 2025-12
Indexed literature (PubMed)12
Vaidya A et al. · JAMA · 2025
El-Maouche D et al. · Lancet · 2017
Burke CW · Clin Endocrinol Metab · 1985
Lefebvre H · Ann Endocrinol (Paris) · 2012
Ng SM et al. · Arch Dis Child · 2016
Reimondo G et al. · Pituitary · 2008
Shimizu H et al. · Clin Transl Sci · 2024
O'Callaghan FJ et al. · Lancet Neurol · 2017
Loriaux DL et al. · Curr Opin Endocrinol Diabetes Obes · 2009
Deinum J et al. · Eur J Endocrinol · 2019
Lux AL et al. · Lancet Neurol · 2005
Bradbury CL et al. · Acta Anaesthesiol Scand · 2013
Keep reading